<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149746</url>
  </required_header>
  <id_info>
    <org_study_id>2004-824</org_study_id>
    <nct_id>NCT01149746</nct_id>
  </id_info>
  <brief_title>Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions</brief_title>
  <official_title>A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the comparative bioavailability between Tamsulosin
      Hydrochloride 0.4 mg Capsules (Teva Pharmaceuticals USA) and Flomax速 0.4 mg Capsules
      (Boehringer Ingelheim Pharmaceuticals, Inc. USA), after a single-dose in healthy subjects
      under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of drug substance in plasma)</measure>
    <time_frame>Blood samples drawn over 60 hour time period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)</measure>
    <time_frame>Blood samples drawn over 60 hour time period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (area under the concentration-time curve from time zero to infinity)</measure>
    <time_frame>Blood samples drawn over 60 hour time period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flomax速</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 mg Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Test 0.4 mg Capsule</description>
    <arm_group_label>Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Reference Listed 0.4 mg Capsule</description>
    <arm_group_label>Flomax速</arm_group_label>
    <other_name>Flomax速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking male subjects, 18 years of age or older.

          -  BMI greater than or equal to 19 and less than or equal to 30.

          -  Negative for:

               -  HIV.

               -  Hepatitis B surface antigen and Hepatitis C antibody.

               -  Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine,
                  opiates, benzodiazepines and methadone).

               -  Urine cotinine test

          -  No significant diseases or clinically significant findings in a physical examination.

          -  No clinically significant abnormal laboratory values.

          -  No clinically significant findings in vital signs measurements and a 12-lead
             electrocardiogram (ECG).

          -  Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between
             60-90 mmgHg.

          -  Be informed of the nature of the study and given written consent prior to receiving
             any study procedure.

        Exclusion Criteria:

          -  Known history or presence of any clinically significant medical condition, illness or
             surgery within 4 weeks prior to drug administration.

          -  Known or suspected carcinoma.

          -  Known history or presence of:

               -  Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug
                  substances with similar activity.

               -  Alcoholism within the last 12 months.

               -  Drug dependence and/or substance abuse.

               -  Use of tobacco or nicotine-containing products within the last 6 months.

          -  Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any
             over the counter (OTC) medication within 7 days prior to Period 1 dosing.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to Period 1 dosing.

          -  On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein,
             raw food diet).

          -  Participated in another clinical trial or received and investigational product within
             30 days prior to drug administration.

          -  Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500
             mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the
             previous 56 days (based on the Canadian Blood Services guideline for blood donation.

          -  Difficulty fasting or consuming the standard meals.

          -  Do not tolerate venipuncture.

          -  Unable to read or sign the ICF.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueyu (Eric) Chen, M.D., Ph. D., FRCP (C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1R 5A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>June 22, 2010</last_update_submitted>
  <last_update_submitted_qc>June 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Associate Director, Biopharmaceutics</name_title>
    <organization>Teva Pharmaceuticals USA</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 18, 2010</submitted>
    <returned>September 10, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

